Xanomeline/Trospium Combination for Alzheimer's Disease Agitation
Fuente:
Zenodo
Salvato in:
| Autore principale: | |
|---|---|
| Natura: | Recurso digital |
| Pubblicazione: |
Zenodo
2026
|
| Soggetti: | |
| Accesso online: | |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
| _version_ | 1866901253269749760 |
|---|---|
| author | MedicOath Autonomous Discovery Engine |
| author_facet | MedicOath Autonomous Discovery Engine |
| contents | Xanomeline acts as a selective M1/M4 muscarinic receptor agonist, targeting cholinergic dysfunction in Alzheimer's disease, while trospium chloride serves as a peripheral anticholinergic to mitigate side effects. This combination addresses both cognitive decline and behavioral symptoms by enhancing central cholinergic signaling while blocking peripheral muscarinic effects. |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_19832463 |
| institution | Zenodo |
| language | |
| publishDate | 2026 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Xanomeline/Trospium Combination for Alzheimer's Disease Agitation MedicOath Autonomous Discovery Engine dementia drug repurposing MedicOath combination Xanomeline acts as a selective M1/M4 muscarinic receptor agonist, targeting cholinergic dysfunction in Alzheimer's disease, while trospium chloride serves as a peripheral anticholinergic to mitigate side effects. This combination addresses both cognitive decline and behavioral symptoms by enhancing central cholinergic signaling while blocking peripheral muscarinic effects. |
| title | Xanomeline/Trospium Combination for Alzheimer's Disease Agitation |
| topic | dementia drug repurposing MedicOath combination |
| url | https://doi.org/10.5281/zenodo.19832463 |